Piracetam
The original racetam and prototype nootropic, developed in 1964. Modulates AMPA receptors, enhances membrane fluidity, and improves cerebral microcirculation. Not metabolised; excreted unchanged renally. Linear pharmacokinetics across 0.8-12 g dose range.
Projected serum levels — 2.4k mg, twice daily
Maintenance schedule: 2.4k mg twice daily (oral).
Modeled steady state after ~1 days: peak ≈ 2.0k mg, trough ≈ 208 mg body load. Population-based estimate over 15 days for a 2.4k mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Racetam
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 5 h
- Common dose
- 2.4k mg
- Suggested maximum
- 4.8k mg/day
- Reference dose range
- 1.2k–4.8k mg (single dose)
- Suggested cadence
- twice daily
- Validated against
- 2.4k mg oral — Cmax 50 mg/L at 0.75 h
Documented interactions
-
warning
Aspirin (Acetylsalicylic Acid) + Piracetam
Piracetam has antiplatelet and antithrombotic properties (reduces platelet aggregation, improves erythrocyte deformability). Combined with aspirin, bleeding risk may be increased.
Serum checks 1 modeled interaction pairings for piracetam across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Clinical efficacy of piracetam in cognitive impairment: a meta-analysis
Meta-analysis of 19 double-blind, placebo-controlled studies in dementia/cognitive impairment found compelling evidence for piracetam global efficacy based on clinical global impression of change.
-
Cognitive effects of piracetam in adults with memory impairment: A systematic review and meta-analysis
Systematic review of 18 RCTs (886 patients) found trends for memory enhancement with piracetam but high heterogeneity limited definitive conclusions on memory function improvement.
-
Effect of piracetam on the cognitive performance of patients undergoing coronary bypass surgery: A meta-analysis
Meta-analysis demonstrated that perioperative piracetam administration significantly improved cognitive outcomes in patients undergoing coronary artery bypass grafting.
-
Pharmacokinetics of piracetam: a study on the bioavailability with special regard to renal and non-renal elimination.
This citation reports a human clinical study involving Piracetam. It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.
4 published studies referenced in the app, each with a plain-language summary.